OBJECTIVE: To analyze the experience in daily clinical practice of interferon-beta ( @entity2391 ) treatment in relapsing-remitting (RR) and secondary progressive (SP) @entity15 ( @entity15 ) in Galicia (Spain). @entity1 AND METHODS: @entity1 with @entity15 treated with @entity686 b between 1995 and December/2000, analyzing demographic and clinical data. RESULTS: 313 @entity1 were included, with a mean age of 38.2 years. A total of 296 @entity1 (94.6%) were clinically defined @entity15 and 17 (5.4%) were laboratory supported (Poser criteria); 84.6% of the @entity1 were RR and 15.4% were SP. The mean duration of the disease prior to treatment was 7.06 years. Betaferon was used in 52.4% @entity1 (115 RR- @entity15 and 47 SP- @entity15 ), Avonex in 26% and Rebif in 21.6%. Relapse rate was reduced in 68.8% for the RR- @entity15 for @entity8975 -treated @entity1 , 73.3% for Avonex treated and 35.7% for Rebif-treated @entity1 . Betaferon reduced relapse rate in 50% for SP- @entity15 . The global EDSS remained stable during @entity2391 treatment. During treatment, 33% of Betaferon, 60.5% of Avonex and 54.5% of Rebif-treated @entity1 remained relapse-free. Treatment was suspended in 12.9% of Betaferon, 6.2% of Avonex, and 3% Rebif-treated @entity1 . The most frequent causes of treatment suspension were @entity717 and in relapse count. CONCLUSIONS: The present study supports the benefits of @entity2391 treatment in RR @entity15 and SP @entity15 in daily clinical practice, with reduction in relapses count and incapacity, good over-all tolerance and low incidence of serious adverse side-effects.

[Experience in the treatment of XXXX with interferon beta in Galicia].

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'PATIENTS'] @entity686 :: ('3438', 'Gene') :: ['IFN-beta1a and 1'] @entity2391 :: ('3456', 'Gene') :: ['IFN-beta'] @entity717 :: ('MESH:D009069', 'Disease') :: ['increase in disability'] @entity8975 :: ('MESH:C044327', 'Chemical') :: ['Betaferon'] @entity15 :: ('MESH:D009103', 'Disease') :: ['MS', 'multiple sclerosis', 'RR-MS and SP-MS']
@entity15 :: (MESH:D009103,Disease) :: ['multiple sclerosis']
